Pfizer/BioNTech , Says Booster Dose Is , 95.6% Effective in Phase 3 Trial.
On October 21, Pfizer/BioNTech said that a booster dose of their coronavirus vaccine was found to have a
high efficacy rate in a Phase 3 trial.
Pfizer/BioNTech said that
a booster dose was 95.6% effective, "irrespective of age, sex, race,
ethnicity or comorbid conditions.".
CNN reports that the trial included over
10,000 fully-vaccinated people ages 16 and older.
They randomly received either a 30-microgram booster dose of vaccine or a placebo.
Pfizer and BioNTech noted that the results showed
a reduction of disease among those who
had a booster shot versus those who did not.
The companies pointed out that these
are the first results from a randomized,
controlled COVID-19 vaccine booster trial.
These results provide further evidence
of the benefits of boosters
as we aim to keep people
well-protected against this disease. , Albert Bourla, Pfizer Chairman and CEO, via CNN.
In addition to our efforts to increase global
access and uptake among the unvaccinated,
we believe boosters have a critical role
to play in addressing the ongoing public
health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.
In addition to our efforts to increase global
access and uptake among the unvaccinated,
we believe boosters have a critical role
to play in addressing the ongoing public
health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.
We look forward to sharing these
data with health authorities and
working together to determine
how they can be used to support
the rollout of booster doses
around the world, Albert Bourla, Pfizer Chairman and CEO, via CNN